490 related articles for article (PubMed ID: 18854392)
1. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
2. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
[TBL] [Abstract][Full Text] [Related]
3. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
4. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
5. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
6. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
8. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
9. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
[TBL] [Abstract][Full Text] [Related]
10. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
12. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
[TBL] [Abstract][Full Text] [Related]
13. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Luconi M; Mannelli M
Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
[TBL] [Abstract][Full Text] [Related]
14. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
15. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
18. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
19. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
[TBL] [Abstract][Full Text] [Related]
20. Metformin as a new anti-cancer drug in adrenocortical carcinoma.
Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M
Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]